It has frequently been suggested that loss of Bz-microglobulin (B2m) in tumor cells may lead to malignant progression due to escape from immunological recognition. Here, we directly tested the role of fl2m expression in tumorigenicity. A ~2m loss mutant (C4.4-25-), selected from the murine lymphoma Eb4, showed a marked reduction in tumorigenicity as compared with Eb4 in normal C57B1/6 (B6) mice. The reduced tumorigenicity was directly related to ~2m expression. Transfection of an intact murine ~2m gene markedly increased the tumorigenic potential. The reduced tumorigenicity of C4.4-25-compared with fl2m transfected cells was observed also in athymic B6 nu/nu mice, but was abolished in B6 mice depleted of natural killer (NK) 1.1-positive cells. These results show that restoration of B2m expression can promote tumorigenicity and demonstrate for the first time that induction of major histocompatibility complex class I expression by transfection can lead to escape from NK cells in vivo.
M
HC class I expression is often reduced or completely lost in tumors (1) . These molecules serve as restriction elements for CTL by presenting antigenic peptides derived from intracellularly degraded proteins (2) . Thus, it has frequently been suggested that downregulated class I expression may contribute to tumor progression by allowing escape from CTL-mediated lysis. Loss of ~2-microglobulin (/~2m) 1 is one cause of MHC class I deficiency in tumors. In one study of 15 MHC class I-deficient colorectal adenocarcinomas, loss of B2m was responsible for the absence of mature HLA-A, -B, and -C heavy chains in all 15 cases (3). Accordingly, loss of fl2m has been predicted to promote malignancy, although this has never been tested formally.
To experimentally address the role of/~2m in malignancy is not trivial, since target MHC class I molecules appear to have a protective effect against recognition by NK cells (4) . This concept predicts an opposite effect of ~2m loss in tumorigenicity. Loss of/~2m should reduce tumorigenicity due to elimination by NK cells while re-expression should restore it.
We set out to test the role of ~/2m in tumorigenicity in a murine mutant-transfection model. A ~2m-deficient mutant of the highly tumorigenic lymphoma line EL-4 was selected and subsequently transfected with a genomic clone 1 Abbreviations used in this paper: /~gm, /~2-microglobulin; B6, C57B1/6; MNNG, N-methyl-N'-nitrosoguanidin. of the murine •2m b gene. Transfections resulted in class 1-expressing cells which were used together with the 32m-deficient mutant to test tumorigenicity in syngeneic B6 and corresponding athymic B6 nu/nu mice, as well as in B6 (C57B1/6) mice depleted of NK-l.l-positive cells. The outcome of the results was the opposite of that predicted from CTL studies. Loss of ~2m expression was associated with reduced tumorigenicity, and restoration of ~2m expression led to an increased tumorigenic potential.
Materials and Methods

Selection of Mutant Cell Lines and DNA-mediated Gene Transfection.
For selection of the/~2m-deficient mutant C4.4-25-, parental EL-4 (H-2 b) lymphoma ceils were treated twice with 10 pg/ml MNNG (N-methyl-N'-nitrosoguanidin). Surviving cells were subjected to complement treatment (Low Tox Rabbit Complement; Cedarlane, Labs., Ltd., Hornby, Ontario, Canada) after incubation with a mixture of anti-H-2K b and D b mAbs B22.249, K10-56, and 28-8-6S; mAbs (5) . After recovery of surviving cells, the complement treatment was repeated three times. Ceils were then subcloned four times by limiting dilution or single-ceU sorting on a cell sorter (Coulter Corp., Hialeah, FL). Transfection was performed with a genomic fl2m b clone combined on the same plasmid (constructed and kindly provided by Dr. P. Robinson, Medical Research Council, Harrow, UK) as the neo R gene by electroporation, as described (5) . Selection after transfection was carried out in medium with 1.0 mg/ml or geniticin (G418, Gibco Laboratories, Uxbridge, UK). In vitro carried mutant and transfectant lines showed no detectable difference in growth rate in normal tissue culture medium.
Source of Mice, In Vivo Tumorigenicity Tests, and NK Cell Depletion. B6 and BALB/c mice were bred and maintained at the Department of Tumor Biology, Karolinska Institutet, or purchased from ALAB, Sollentuna, Sweden. Athymic B6 nu/nu mice were purchased from G1. Bomholtgard, Ky, Denmark. Mice used in in vivo experiments were 5-8 wk old at the start of the experiments, usually littermates, or otherwise age-matched within 2 wk. Graded doses of in vivo-passaged (6) tumor cells were inoculated either subcutaneously (right flank) or intraperitoneally in a 0.1 ml vol of PBS. Tumors always appeared at the site of inoculation, and tumor growth was followed at least once weekly by palpations and measurements at the tumor site. Mice were killed when the subcutaneous tumors reached a size of >15 mm in diameter, and no signs of rejection were observed. Mice without any signs of tumor growth were kept under observation for at least 30 d after inoculation. Small groups of mice, never exceeding five mice per group, were tested in several independent tests throughout the study to minimize the risk of random fluctuations in the quantity or quality of cells inoculated. For NK cell depletion in vivo, mice were given a single injection of 200 #1 ascites fluid prepared from mice inoculated intraperitoneally with the anti-NKl.1 mAb 1 d before inoculation of tumor cells (7).
Immunoprecipitation and SDS-PAGE. Immunoprecipitation of
MHC class I molecules from [3SS]methionine metabolically labeled cells with a rabbit anti-mouse class I antiserum (K270, kindly provided by Dr. L. Rask, Biomedical Center, Uppsala, Sweden) and subsequent analysis on a 13% SDS-PAGE was carried out as described (8) .
FACS | Analysis. The cell surface expression of H-2D b and K b
shown in Table 1 In Vitro Cell-mediated Cytotoxicity. Anti-H-2b-specific CTL effectors were generated in bulk MLCs by using splenocytes from BALB/c mice, preimmunized with B6 splenocytes, as responders and irradiated splenocytes from B6 mice as stimulators. CTL were H-2 b specific since they also killed other H-2b-expressing targets (RBL-5), but not H-2d-expressing targets (P815) (data not shown). A standard 4-h SlCr-release assay was used to measure cytotoxic activity.
Results and Discussion
FACS | analysis demonstrated that the EL-4-derived C4.4-25-line was class I deficient on the cell surface (Table 1) . This can be explained by lack of 32m expression. No 32m could be coprecipitated with the class I H chains as revealed by immunoprecipitation and subsequent SDS-PAGE analysis (Fig. 1) . Note the total absence of 32m and reduced molecular weight of the class I H chains isolated from the C4.4-25-mutant (Fig. 1) , the latter due to an arrest in transport through the Golgi complex where terminal glycosylation (increasing the mol wt) of class I H chains normally would occur (9) . The mutant was completely resistant to conventional anti-H-2 b allo-specific CTL lysis (Table 1 ). C4.4-25-was transfected with a genomic clone of the murine fl2m b gene. Two transfected clones, E50.15 + and E50.16 +, were isolated for further characterization. These clones both expressed B6 mice, and tumor growth was followed. The C4.4-25-/~2m-deficient mutant line showed a markedly reduced tumorigenic potential compared with the Eb4 wild-type line (Table 2 ). In contrast, the B2m-transfected C4.4-25-line, E50.16 +, had regained tumorigenicity when compared with C4.4-25-. When tumors appeared after inoculation of C4.4-25-mutant cells (Table 2) It should be noted that the tumorigenic potential of the E50.16 + transfectant never reached that of the EL-4 wildtype line although it was significantly increased compared with the C4.4-25-line (Table 2 ). This result, at least partly, may be a reflection of the small (but consistent) reduction of class I levels on E50.16 + compared with the Eb4 wildtype line (Table 1 ). E50.16 § was also slightly less killed by CTL than EL,4 ( Table 1 ). Note that the E50.16 + line was somewhat more tumorigenic in NKl.l-depleted mice than in normal untreated B6 mice (Table 2) , which is consistent with a significantly reduced, but not totally abrogated NKsensitive phenotype in vivo.
To our knowledge, this is the first time that the ~2m gene directly has been demonstrated to protect a tumor from rejection and thus promote tumorigenicity. The results suggest that the effect of 32m is due to altered interactions with the host, not due to the intrinsic growth properties. We condude that NK cells eliminate the C4.4-25-cells because of the MHC class I-deficient phenotype and that this elimination is abrogated by restoration of MHC class I expression at the cell surface. The results fit with in vitro results, demonstrating that NK cells can recognize and kill cells that fail to express MHC class I molecules, but not similar cells after restoration of MHC class I expression by class I/fl2m transfee*ion (reviewed in reference 4). They also support earlier studies in which MHC class I-deficient lymphoma cells were shown to be eliminated by NK cells in vivo (6, 10) . The present results are in line with the observation that expression of recipient MHC class I molecules can protect tumor or bone marrow grafts from rapid dimination by NK cells. Expression of a H-2D d transgene protects B6 bone marrow, as well as lymphoma cells from rejection in H-2D a transgenic B6 mice (11) (12) (13) . Furthermore, 32m-deficient bone marrow cells are rejected by fl2m-expressing mice, and the marrow from flzm +/-littermates is accepted (14; (3hlrn et al., manuscript submitted for publication).
The present results differ from several earlier studies of was seen after subcutane-MHC-dependent tumor rejection, many of which were performed with highly antigenic tumors, where transfection of class I molecules resulted in loss of tumorigenicity through escape from T cell immunity (reviewed in reference 15). Tumorigenicity can also be altered by MHC class I transfection through mechanisms independent of the host immune response (16, 17) . Our results demonstrate a third possibility: reduced tumorigenicity associated with loss of class I expression due to NK ceU-mediated rejection.
This does not permit the generalized conclusion that ~/2m
is a malignancy-promoting gene. The effects of variations in class I expression will depend on the dominating immunosurveillance system in a certain situation, i.e., NK-(eliminating class I-deficient cells) or T cells (restricted to elimination of class I-positive cells if these harbor antigenic peptides bound to the class I antigen-binding groove) (discussed in reference 4). However, the present study demonstrates that restoration of B2m/class I expression, under certain circumstances, can lead to increased tumorigenicity.
